Diabetes Therapeutic
Diabetes
Not specifiedActive
Key Facts
About Housey Pharmaceutical Research Laboratories
Housey Pharma is a unique hybrid entity combining internal therapeutic development with a successful technology licensing business. Its core strategy involves leveraging proprietary, internally invented drug discovery platforms to advance its own pipeline while generating revenue through licensing agreements with major pharmaceutical companies like Novartis. The company's pipeline includes both prescription therapeutics and a marketed product, Axulin, and is supported by a leadership team and advisory board with deep industry and scientific expertise. Its dual model of platform licensing and product development positions it in both the technology and therapeutics sectors of biopharma.
View full company profileOther Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| AdOral® Insulin | Adocia | Preclinical |
| Oral Insulin | Premas Biotech | Phase 3 |
| PRX-3140 | Nanopharmaceutics | Clinical |
| Insulin Program | Biolingus | Pre-clinical |
| Insulin Aspart Biosimilar | Meitheal Pharmaceuticals | Preclinical |
| Insulin Glargine Biosimilar | Meitheal Pharmaceuticals | Preclinical |
| Insulin Lispro Biosimilar | Meitheal Pharmaceuticals | Preclinical |
| Liraglutide Injection | Meitheal Pharmaceuticals | Approved |
| Diabetes Clinical Trials | DM Clinical Research | Not Specified |
| Diabetes Research | Evidation Health | Research |
| Injectable HDV-Rapid Acting Insulin (Open Label, MoA) | Diasome Pharmaceuticals | Phase 2 |
| Glucose-Responsive Insulin Receptor Agonist | Protomer Technologies | Pre-clinical (integrated into Lilly pipeline) |